tiprankstipranks

Evolus expects FDA approval for Evolysse within 90 days, ahead of schedule

“Our U.S. filing for Evolysse is ahead of schedule, and we now expect to receive FDA approval within the next 90 days. Next quarter, we will reach an important milestone, transitioning from a single product company to a multi-product innovator,” Moatazedi continued. “Our scalable cash-pay model, combined with a differentiated product portfolio, deep customer engagement, and leverageable infrastructure positions us for continued success. With the upcoming launch of Evolysse injectable HA gels and sustained strength of Jeuveau and Nuceiva, our leadership in performance beauty continues to strengthen and we are well-positioned to achieve another year of over 30% revenue expansion. Looking beyond 2025, we are focused on achieving at least $700 million in net revenue and non-GAAP operating income margin of at least 20% by 2028, driven by our disciplined financial management and strategic investments.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue